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ABSTRACT 
Second order derivative spectroscopy method was developed and validated for the simultaneous estimation of Diclofenac sodium (DFS) and 
Serratiopeptidase (SPD) in bulk and tablet dosage form. Accurate and Précised UV Spectrophotometric method with good sensitivity has been 
developed for simultaneous estimation of DFS and SPD. The method employs Second order derivative based on the measurement of absorbance 
of DFS at ZCP 264.20 nm and SPD at ZCP 295.20 nm. The calibration curve was linear in a concentration range of 5-30 μg/ml for DFS and 25-
150 μg/ml for SPD. The developed method was validated as per ICH guideline, for its accuracy, precision, LOD, LOQ and the results were found 
to be satisfactory, thus the method is specific, rapid and simple with good sensitivity for estimation of DFS and SPD in marketed dosage form. 
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INTRODUCTION: 
Diclofenac Sodium belongs to the class of Non-steroidal Anti-
inflammatory Agents (NSAIAs) whereas Serratiopeptidase 
belongs to Proteolytic enzyme (protease). Diclofenac Sodium 
also has Antipyretic and Analgesic action. It is primarily 
available as the sodium salt. Serratiopeptidase (Serratia E-15 
protease, also known as serralysin, serratiapeptase, serratia 
peptidase, serratio peptidase, or serrapeptidase) is a 
proteolytic enzyme (protease) produced by enterobacterium 
Serratia sp. E-15. The structures of Diclofenac Sodium and 
Serratiopeptidase are shown in figure1.1    
Analytical method development and validation play an 
important role in the drug discovery, development, and 
manufacture of pharmaceuticals. The official test methods 
that result from analytical method development are used by 
quality control laboratories to ensure the identity, purity, 
potency, and performance of drug products and to ensure 
compliance with quality and safety standards. 1 
 
 
 
Figure: 1 Structure of Diclofenac Sodium and 
Serratiopeptidase 
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Derivative zero crossing Spectrophotometry: 
It is a useful means of resolving the overlapping spectra and 
eliminating the interference. It involves conversion of normal 
spectrum to first, second or higher order spectras where the 
amplitude in the derivative spectra is proportional to the 
concentration of analyte provided the Beers law is obeyed. 
The successive development of the zero-crossing technique 
was accordingly due to the feature of derivative spectra to 
show signals with both positive and negative value. This 
technique exploits the signal crossing through the abscissa 
axis, for a given component of a mixture, to assign the 
absorbance value to remaining components. Zero crossing 
technique is particularly effective in the analysis of several 
complex mixtures, when wide peaks overlapping are present 
in the corresponding zero-order spectrum.  
However, suitable analytical signals are often placed on the 
peak shoulders or characterized by a too low absorbance. 
This could heavily limit the accuracy and precision of the 
method, as the low stability of such signals is well known. 2 
Literature review reveals that there are several 
spectroscopic methods like First order derivative and 
Absorption ratio methods reported for the estimation of 
Diclofenac Sodium and Serratiopeptidase. But second order 
derivative method is not reported for this combination. 
Hence it was thought worthwhile to develop analytical 
methods for simultaneous determination of Diclofenac 
Sodium & Serratiopeptidase in their bulk form and tablet 
dosage form. 3 4 5 6   
MATERIALS AND METHODS 
Instrument: 
 Double beam UV-spectrophotometer (Shimadzu-1800) 
 UV Probe Version 1.03 
 Shimadzu electronic balance BL220H  
 Sonicator : Ultrasonic Cleaner  
Materials: 
 API     Serratiopeptidase ( as gift sample procured  from 
OM lab) 
 API     Diclofenac Sodium 
 CIPZEN - D tablets (label claim 50  mg Diclo + 10 mg 
Serratio) 
All apparatus and instrument were calibrated and validated 
as per SOP/protocol before starting the experimental work
. 
 
Reagents and Chemicals:  
Table:1 List of Chemicals and Reagents 
Sr. No. Chemicals/Reagents Grade Company 
1 Acetonitrile HPLC Merck 
2 Methanol HPLC Merck 
3 Water HPLC Merck 
4 Ethanol NA Merck 
5 Potassium dihydrogen phosphate monobasic HPLC Spectro chem 
6 Acetone NA Merck 
7 0.1 HCl NA NA 
 
Marketed formulation: 
CIPZEN - D tablet  
Label claim: Diclofenac sodium 50 mg 
                      Serratiopeptidase10 mg 
Identification of Pure Drug  
Melting point determination  
It was carried out by Capillary melting point method. A 
few amount of the compound was placed in a thin wall 
capillary tube 10-15 cm long, about 1 mm in inside diameter, 
and fused at one end. The capillary containing the sample 
and a thermometer was suspended in oil bath so that they 
can be heated slowly and evenly. The temperature range 
over which the sample was melted, taken as the melting 
point. And it was compare with standard. 7 
Solubility  
Solubility of compound was determined by UV spectroscopy. 
In this method, saturated solution of compound was 
prepared in solvent such as water, methanol, acetonitrile and 
phosphate buffer. Further it was kept for 24 h filtered and 
the filtrate was used for further analysis and the absorbance 
was measured at 274nm and 276nm. Further on the basis of 
absorbance the drug concentration was calculated in mg/ml. 
7 
IR identification   
Fourier Transform Infrared Spectroscopy was carried out for 
solid samples to identify the presence of various functional 
groups present in drug. The samples were prepared by the 
potassium bromide disc method. Powders (20mg drug in 
280mg KBr) were triturated in agate mortar and pestle to 
produce fine and uniform mixture. The pellets were 
prepared by compressing the powders at 20 psi for 10 min 
using Potassium bromide - press. Pure potassium bromide 
powder was used as background, and for baseline correction. 
Prepared sample disc was placed in a sample holder and 
transferred to sample compartment. Samples were scanned 
in the region of 4000-400 cm-1 using a bruker FTIR 
spectrometer and it was compared with standard. 7 
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Development of UV Second Order Derivative 
Spectroscopy: 
Condition used:  
 Mode : Spectrum  
 Scan speed : Medium  
 Wavelength range : 200-400 nm  
 Derivative order : 2  
 Delta lamda : 8 nm  
 Scaling factor : 10  
Selection of solvent for Diclofenac sodium and 
Serratiopeptidase: 
Many solvents like Water, Methanol, 0.1N Sodium Hydroxide 
(NaOH), and Ethanol were tried for better analysis. Among 
all, water was selected as the best solvent for UV analysis. 
The overlain spectra of Diclofenac sodium and 
Serratiopeptidase were overlapped which showed a 
feasibility of using this solvent for Spectrophotometric 
analysis with concern to simultaneous estimation of these 
drugs. 
Selection of analytical wavelength for Diclofenac sodium 
and Serratiopeptidase:  
5-30 μg/ml solutions of Diclofenac sodium were prepared in 
water and spectrum was recorded between 200-400 nm. 
Second derivative spectrums for above concentration were 
taken. Similarly 25-150 μg/ml solutions of Serratiopeptidase 
were prepared in water and spectrum was recorded between 
200-400 nm and Second derivative spectrums were taken. 
The derivative spectra of Diclofenac sodium and 
Serratiopeptidase at different concentration were recorded. 
The zero crossing point (ZCP) of Diclofenac sodium at which 
Serratiopeptidase is measured and ZCP of Serratiopeptidase 
at which Diclofenac sodium was measured for the overlain 
spectra of both.  
Preparation of standard stock solution  
Diclofenac sodium standard stock solution: (100 μg/ml): 
A 10 mg of standard Diclofenac sodium was weighed and 
transferred to a 100 ml volumetric flask and dissolved in 25 
ml water. The flask was shaken and volume was made up to 
the mark with water to give a solution containing 100μg/ml 
Diclofenac sodium. 
Serratiopeptidase standard stock solution: (500 μg/ml): 
A 50 mg of Serratiopeptidase standard was accurately 
weighed and transferred to a 100 ml volumetric flask and 
dissolved in 25 ml water. The flask was Sonicated for 10 
minutes and volume was made up to the mark with methanol 
to give a solution containing 500μg/ml Serratiopeptidase.  
Calibration curve for Diclofenac sodium and 
Serratiopeptidase  
Calibration curve of Diclofenac sodium (5-30 μg/ml)  
Appropriate volume of aliquots from standard Diclofenac 
sodium stock solutions were transferred to different 
volumetric flasks of 10 ml capacity. The volume was adjusted 
to the mark with the water to obtain concentration of and 5, 
10, 15, 20, 25 and 30 μg/ml. The second derivative (D2) 
curve of each solution was recorded. D2 absorbance at ZCP 
of Serratiopeptidase was measured and the plot of D2 
absorbance vs. concentration was plotted. The straight-line 
equation was determined.  
Calibration curve of Serratiopeptidase (25-150 μg/ml)  
Appropriate volume of aliquots from standard 
Serratiopeptidase stock solutions was transferred to 
different volumetric flasks of 10 ml capacity. The volume was 
adjusted to the mark with the water to obtain concentration 
of 25, 50, 75, 100, 125 and 150 μg/ml. The second derivative 
(D2) curve of each solution was recorded. D2 absorbance at 
Diclofenac sodium was measured and the plot of D2 
absorbance vs. concentration was plotted. The straight-line 
equation was determined.  
Linearity  
The linearity response was determined by analyzing 
independent levels of concentrations in the range of 5-30 
and 25-150 μg/ml for Diclofenac sodium and 
Serratiopeptidase respectively. Absorbance of each solution 
was measured at ZCP of Serratiopeptidase and Diclofenac 
sodium respectively using developed method. Calibration 
curve of absorbance Vs concentration was plotted and the 
correlation coefficient, regression line equations for 
Diclofenac sodium and Serratiopeptidase were determined 
respectively. 
Accuracy  
The accuracy studies were carried out by addition of 
standard drug to the sample at 3 different concentration 
levels (50, 100 and 150 %) taking into consideration 
percentage purity of added bulk drug samples. It was 
determined by calculating the recovery of Diclofenac sodium 
and Serratiopeptidase by standard addition method. 
Accuracy is the closeness of the test results obtained by the 
method to the true value.  
Precision  
1. Repeatability  
6 replicates of 20 μg/ml concentrations of Diclofenac sodium 
and 100 μg/ml of Serratiopeptidase were prepared and 
absorbance was measured at ZCP of Serratiopeptidase and 
Diclofenac sodium respectively. SD and %RSD were 
calculated.  
2 Interday precision  
Standard solutions containing 10, 20 and 30 μg/ml 
Diclofenac sodium and 50, 100 and 150μg/ml 
Serratiopeptidase were analyzed on three different days as 
per the procedure. The absorbance of solutions was 
measured at ZCP of Serratiopeptidase and Diclofenac sodium 
respectively. SD and %RSD were calculated  
3 Intraday precision  
Standard solutions containing 10, 20 and 30 μg/ml 
Diclofenac sodium and 50, 100 and 150μg/ml 
Serratiopeptidase were analyzed 3 times on the same day as 
per the procedure. The absorbance of solutions was 
measured at ZCP of Serratiopeptidase and Diclofenac sodium 
respectively. SD and %RSD were calculated.   
 Limit of Detection  
Calibration curve was carried out for 6 times and the 
standard deviation (SD) of the intercepts were calculated by 
the formula as mentioned below:  
LOD= (3.3*SD)/Slope  
Where, SD = the standard deviation of Y- intercept of 6 
calibration curves.  
Slope = the mean slope of the 6 calibration curves.  
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 Limit of Quantitation  
Calibration curve was repeated for 6 times and the standard 
deviation (SD) of the intercepts was calculated by the 
formula as specified below: 
LOQ= (10*SD)/Slope  
Where, SD = the standard deviation of Y- intercept of 6 
calibration curves.  
Slope = the mean slope of the 6 calibration curves.   
Robustness  
For the determination of robustness 3 different mixture of 
same concentration of samples were analyzed at different 
wavelength. The absorbance at 263.2, 264.2 and 265.2 nm 
and 294.2, 295.2 and 296.2 nm were recorded and %R.S.D. 
was calculated. 
Determination of Diclofenac sodium and 
Serratiopeptidase in their tablet dosage form (Assay) 
(Standard addition method)  
Sample preparation  
For estimation of Diclofenac sodium and Serratiopeptidase, 
20 tablets were weighted and powdered with the help of 
mortar and pestle. A quantity of the powdered tablet 
equivalent to 50 mg of Diclofenac sodium and 10 mg of 
Serratiopeptidase was weighed accurately and 240 mg 
standard Serratiopeptidase powder was added into it 
(standard addition) and transferred to volumetric flask of 
100 ml capacity. 100 ml of water was transferred to this 
volumetric flask and sonicated for 15 min. The flask was 
shaken and volume was made up to the mark with water. 
The above solution was filtered through whatman filter 
paper (0.45μ). From this solution 20 ml was transferred to 
volumetric flask of 100 ml capacity. Volume was made up to 
the mark to give a solution containing 100 μg/ml Diclofenac 
sodium and 500 μg/ml Serratiopeptidase (solution A). From 
the solution A, 4 ml was transferred to volumetric flask of 
100 ml capacity and volume was made up to the mark to give 
a solution containing 20 μg/ml Diclofenac sodium and 100 
μg/ml Serratiopeptidase. This solution was used for the 
estimation of Diclofenac sodium and Serratiopeptidase. 
 Estimation of Diclofenac sodium and Serratiopeptidase  
The derivative response of above solution was measured at 
ZCP of Serratiopeptidase for Diclofenac sodium and at ZCP of 
Diclofenac sodium for quantification of Serratiopeptidase 
respectively. The amount of Diclofenac sodium and 
Serratiopeptidase present in the sample solution were 
determined by fitting derivative responses into the equation 
of the straight line representing the calibration curves for 
Diclofenac sodium and Serratiopeptidase.  
RESULT AND DISCUSSION 
Identification of drugs: 
Melting Point: 
Table 2: Melting Point of Diclofenac sodium 
and Serratiopeptidase 
APIs Observed Standard 
Diclofenac sodium 164-166°C 163-168°C 
Serratiopeptidase 284-286°C 283-285°C 
 
Solubility Study:  
Diclofenac sodium : Soluble in water, Acetone, Ethanol, 
Methanol, Acetonitrile   
Serratiopeptidase :  Soluble in water 
Discussion: From the obtained result, Serratiopeptidase was 
found to be soluble in water. Diclofenac sodium was found to 
be soluble in water, methanol, Acetonitrile (ACN), and 
Ethanol. Therefore, single solvent water could be used for 
estimation of both drugs. 
IR Identification: 
Diclofenac sodium FTIR spectra: 
 
 
Figure 2 : FTIR spectrum of Diclofenac sodium (Reference-As per IP 2010) 
 
Figure 3: FTIR spectrum of Diclofenac sodium 
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Discussion: IR spectrum of Diclofenac sodium sample was interpreted. From these, we can say that the given sample may be 
Diclofenac sodium. 
Serratiopeptidase: 
 
Figure 4: FTIR spectrum of Serratiopeptidase 
Table 4: IR interpretation of Serratiopeptidase 
Sr.No  Frequency(cm-1)  Characteristics  
1  3287.60  N-H Stretching  
2  2932.92  C-H Aliphatic 
stretching  
3  1649.08  C=O Stretching  
4  1543.19  Aromatic ring  
5  1251.45  C-N Stretching  
6  1075.53  C-O Stretching  
7  771.33  C-F  
 
 
Discussion: IR spectrum of Serratiopeptidase sample was 
interpreted. From these, we can say that the given sample 
may be Serratiopeptidase. 
Method Development by Second Order Derivative UV 
Spectroscopy: 
Selection of solvent for Diclofenac sodium and 
Serratiopeptidase:  
Water was selected as solvent because both the drugs were 
soluble in it and spectra of Diclofenac sodium and 
Serratiopeptidase, when overlapped, show feasibility of 
using this solvent for Spectrophotometric analysis for their 
estimation by UV method.  
 
Table 3: IR interpretation of Diclofenac sodium 
Sr. No.  Frequency(cm-1)  Characteristics  
1  3383.63  N-H stretch  
2  2970.06  Aliphatic C-H stretching  
3  1573.61  C=O stretching of carboxyl ion  
4  1504.03  Aromatic ring  
5  1283.31  Skeletal C=C vibration  
6  1169.92  C-O stretch  
7  1090.79  Aromatic C-H in-plane bend  
8  767.99  C-Cl  
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Analytical wavelength for Diclofenac sodium and Serratiopeptidase: 
 
 
Figure 5: Second order derivative spectrum overlay of Diclofenac sodium (15 μg/ml) and Serratiopeptidase (75 μg/ml) 
 
 
Figure 6: Second order derivative spectrum overlay of Diclofenac sodium (5-30 μg/ml) and Serratiopeptidase (25-150 
μg/ml) 
 
Discussion: The zero crossing point (ZCP) of Diclofenac 
sodium was 295.20 nm where second order derivative of 
Serratiopeptidase measured and ZCP of Serratiopeptidase 
was 264.20 nm where second derivative of Diclofenac 
sodium measured. 
Validation of UV Spectrophotometric Method:  
Linearity  
Calibration curve for the Diclofenac sodium (5-30 
μg/ml)  
Absorbance at 264.20 nm ZCP of Serratiopeptidase was 
measured for following concentrations 5, 10, 15, 20, 25 and 
30 μg/ml. Absorbances were obtained and the graph of 
calibration curve was obtained.  
 
 
 
 
 
Table 5: Calibration curve for Diclofenac sodium 
Conc. (μg/ml) Mean Absorbance ± S.D. 
5 0.0019 ± 0.00015 
10 0.0036 ± 0.00010 
15 0.0054 ± 0.00015 
20 0.0072 ± 0.00025 
25 0.0088 ± 0.00025 
30 0.0108 ± 0.00032 
295.20 nm ZCP of Diclofenac Sodium 
264.20 nm ZCP of Serratiopeptidase 
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Figure7: Graph of Calibration curve for Diclofenac 
Sodium 
Discussion: Linearity range for Serratiopeptidase was found 
to be 25-150 μg/ml in. water. Regression Equation for 
Serratiopeptidase at 295.20 nm: Y= 0.0001x+ 0.00002. R2 
value: 0.9989.   
Calibration curve for the Serratiopeptidase (25-150 
μg/ml)  
Table 6: Calibration curve for Serratiopeptidase 
Conc. (μg/ml) Mean Absorbance ± S.D. 
25 0.0028 ± 0.00011 
50 0.0055 ± 0.00015 
75 0.0084 ± 0.00015 
100 0.0116 ± 0.00010 
125 0.0140 ± 0.00015 
150 0.0168 ± 0.00020 
 
Absorbances at 295.20 nm ZCP of Serratiopeptidase were 
measured for following concentrations 25, 50,75,100, 125 
and 150μg/ml. Absorbances were obtained and the graph of 
calibration curve was obtained.  
 
Figure 8: Graph of Calibration curve for 
Serratiopeptidase 
Discussion: Linearity range for Serratiopeptidase was found 
to be 25-150 μg/ml in. water. Regression Equation for 
Serratiopeptidase at 295.20 nm: Y= 0.0001x+ 0.00002. R2 
value: 0.9989. 
Accuracy  
Diclofenac sodium  
Concentration of Preanalyzed sample of Diclofenac 
sodium: 10μg/ml 
  
 
Table 7: Accuracy data of Diclofenac sodium 
Level Amt of 
added 
std 
(μg/ml) 
Total 
conc. 
(μg/ml) 
Abs Avg. Abs. Conc. 
found 
(μg/ml) 
% recovery Mean 
± 
SD 
50% 5 15 0.0059 0.00606 14.94 99.60 100.39 ± 
0.745 5 15 0.0061 
5 15 0.0062 
100% 10 20 0.0081 0.00813 20.10 100.50 
10 20 0.0080 
10 20 0.0083 
150% 15 25 0.0101 0.0102 25.27 101.08 
15 25 0.0103 
15 25 0.0102 
 
Discussion: Result obtained reveals that % recovery of Diclofenac sodium was within acceptance criteria given in ICH i.e. 98-
102%. 
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Serratiopeptidase  
Concentration of Preanalyzed sample of Serratiopeptidase: 50μg/ml 
Table  8 : Accuracy data of Serratiopeptidase 
Level  Amt of added std 
(μg/ml)  
Total conc.  
(μg/ml)  
Abs  Avg. Abs.  Conc.  
found  
(μg/ml)  
% 
recovery  
Mean  
±  
SD  
50% 25 75 0.0073 0.0074 25.11 98.93 99.38± 
0.465 25 75 0.0074 
25 75 0.0075 
100% 50 100 0.0100 0.00996 99.67 99.86 
50 100 0.0099 
50 100 0.0100 
150% 75 125 0.0123 0.0124 124.20 99.36 
75 125 0.0125 
75 125 0.0124 
Discussion: Result obtained reveals that % recovery of Serratiopeptidase was within acceptance criteria given in ICH i.e. 98-
102%. 
 
Precision  
Repeatability  
Table 9: Repeatability data of Diclofenac sodium and Serratiopeptidase 
Standard drug Target conc. 
(μg/ml) 
Abs of sample Conc. found 
(μg/ml) 
Mean SD %RSD 
Diclofenac sodium 
 
20 0.0079 19.525 19.48 0.188 0.965 
20 0.0079 19.525 
20 0.0080 19.775 
20 0.0078 19.225 
20 0.0078 19.225 
20 0.0079 19.525 
Serratiopeptidase 100 0.0101 101.2 100.03 0.752 0.752 
100 0.0100 100.2 
100 0.0100 100.2 
100 0.0099 99.2 
100 0.0099 99.2 
100 0.0100 100.2 
 
Discussion: The % RSD for Repeatability of both the drugs was found to be less than 2. So, it was concluded that proposed 
method for estimation of Diclofenac sodium and Serratiopeptidase is précised in nature. 
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Interday precision:  
Table 10: Interday precision data for Diclofenac sodium 
Conc. 
(μg/ml) 
Absorbance Conc. found (μg/ml) Mean ± S.D. %RSD 
1 2 3 1 2 3 
10 0.0041 0.0042 0.0041 10.025 10.275 10.025 10.108±0.144 1.42 
20 0.0079 0.0078 0.0076 19.525 19.275 18.775 19.131±0.381 1.98 
30 0.0119 0.0118 0.0121 29.525 29.275 30.225 29.608±0.381 1.28 
 
Table 11: Interday precision data for Serratiopeptidase 
Conc. 
(μg/ml) 
Absorbance Conc. found (μg/ml) Mean ± S.D. %RSD 
1 2 3 1 2 3 
50 0.0050 0.0049 0.0049 50.7 49.7 49.7 49.53±0.577 1.16 
100 0.0100 0.0101 0.0101 100.7 103.7 101.7 101.53±1.527 1.50 
150 0.0147 0.0148 0.0150 147.7 148.7 150.7 148.53±1.527 1.02 
 
Discussion: The % RSD for Interday precision of both the drugs was found to be less than 2. So, it was concluded that proposed 
method for estimation of Diclofenac sodium and Serratiopeptidase is précised in nature. 
Intraday precision   
Table 12: Intraday precision data for Diclofenac sodium 
Conc. 
(μg/ml) 
Absorbance Conc. found (μg/ml) Mean ± S.D. %RSD 
1 2 3 1 2 3 
10 0.0041 0.0042 0.0041 10.025 10.275 10.025 10.108±0.144 1.42 
20 0.0079 0.0081 0.0078 19.525 20.025 19.275 19.608±0.381 1.94 
30 0.0119 0.0120 0.0117 29.525 29.775 29.025 29.441±0.381 1.29 
 
Table 13: Intraday precision data for Serratiopeptidase 
Conc. 
(μg/ml) 
Absorbance Conc. found (μg/ml) Mean ± S.D. %RSD 
1 2 3 1 2 3 
50 0.0050 0.0049 0.0050 50.7 49.7 50.7 49.86±0.5773 1.15 
100 0.0101 0.0100 0.0103 101.7 100.7 103.7 101.53±1.527 1.50 
150 0.0147 0.0146 0.0149 147.7 146.7 149.7 147.53±1.527 1.03 
 
Discussion: The % RSD Intraday precision and Inter day precision for of both the drugs was found to be less than 2. So, it was 
concluded that proposed method for estimation of Diclofenac sodium and Serratiopeptidase is précised in nature. 
Limit of Detection  
Table 14: LOD data Diclofenac sodium and Serratiopeptidase 
Parameter Diclofenac sodium Serratiopeptidase 
Slope (n=6) 0.0004 0.0001 
SD (n=6) 0.00008 0.00004 
LOD (μg/ml) 0.6771 1.3364 
 
Discussion: The proposed method can detect Diclofenac sodium and Serratiopeptidase at very low level .So, it was concluded 
that the proposed method is very sensitive in nature. 
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Limit of Quantitation 
LOQ data for Diclofenac sodium and Serratiopeptidase 
Table 15: LOQ data Diclofenac sodium and Serratiopeptidase 
Parameter Diclofenac sodium Serratiopeptidase 
Slope (n=6) 0.0004 0.0001 
SD (n=6) 0.00008 0.00004 
LOQ (μg/ml) 2.0519 4.0498 
 
Discussion: The proposed method can quantify small amount of drugs with precisely. So, it was concluded that the proposed 
method is very sensitive in nature. 
Robustness  
Table 16: Robustness data for Diclofenac sodium 
Conc. 
(μg/ml) 
Abs. 
at 263.2 
Conc. 1 Abs. 
at 264.2 
Conc. 2 Abs. 
at 265.2 
Conc. 3 
20 0.0063 15.52 0.0079 19.52 0.0094 23.27 
20 0.0064 15.77 0.0078 19.27 0.0093 23.05 
20 0.0063 15.52 0.0081 20.02 0.0096 23.77 
 Mean 15.60  19.60  23.25 
 SD 0.144  0.381  0.38 
 %RSD 0.92  1.94  1.63 
 
Table 17: Robustness data for Serratiopeptidase 
Conc. 
(μg/ml) 
Abs. 
at 294.2 
Conc. 1 Abs. 
at 295.2 
Conc. 2 Abs. 
at 296.2 
Conc. 3 
100 0.0068 68.7 0.0101 101.7 0.0118 118.7 
100 0.0069 69.7 0.0098 98.7 0.0119 119.7 
100 0.0069 69.7 0.0100 100.7 0.0121 121.7 
 Mean 69.36  99.86  119.53 
 SD 0.577  1.527  1.527 
 %RSD 0.83  1.52  1.27 
 
Discussion: The % RSD of Diclofenac sodium and Serratiopeptidase in Robustness study was found to be less than 2 which is 
within the acceptance criteria. 
Derivative spectrum of Diclofenac sodium and Serratiopeptidase in tablet dosage formulation (Assay) (Standard 
Addition Method)  
Table 18: % Assay of Diclofenac sodium and Serratiopeptidase(n=6) 
Drug Conc. in 
formulation 
mg/tablet 
Conc. taken 
for assay 
(μg/ml) 
Abs. of 
sample 
Conc. Found 
(μg/ml) 
%Assay ± S.D. 
Diclofenac 
sodium 
50 mg 20 0.0081 20.025 100.12 ± 0.223 
Serratiopepti
dase 
10 mg 100 0.0100 100.86 100.86 ± 1.722 
 
Discussion: % Assay of Diclofenac sodium and Serratiopeptidase was found in an acceptance limit so this method could be 
used for analysis of this combination. 
Parmar et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4):395-405 
  
ISSN: 2250-1177                                                                                 [405]                                                                               CODEN (USA): JDDTAO 
CONCLUSION 
The present work involves the development and validation 
of a simple, accurate and precise Second order derivative UV 
spectrophotometric method for the assay of Diclofenac 
sodium and Serratiopeptidase was carried out in Tablet 
dosage forms.  
The wavelengths selected for quantitation were 264.2 nm 
for (zero crossing point for Diclofenac sodium) and 295.2 
nm for (zero crossing point for serratiopeptidase). The 
method was validated for linearity, precision, accuracy and 
all the parameters were in line with the standard limits as 
per laid by the pharmacopoeia. The marketed preparation of 
this combination was inline with the sample tested. 
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Abs: Absorbance; Avg: Average; ACN: Acetonitrile; API: 
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Pharmacopoeia; UV: Ultraviolet; Conc.: Concentration; gm: 
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Conference on Harmonization LOD: Limit of Detection; LOQ: 
Limit of Quantification; SD: Standard Deviation; RSD: 
Relative Standard Deviation 
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